Suppr超能文献

纤维蛋白胶可有效治疗克罗恩病患者的肛周瘘。

Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease.

机构信息

Hôpital Nord, Centre d'investigation Clinique Marseille Nord, Université Méditerranée, Marseille, France.

出版信息

Gastroenterology. 2010 Jun;138(7):2275-81, 2281.e1. doi: 10.1053/j.gastro.2010.02.013. Epub 2010 Feb 20.

Abstract

BACKGROUND & AIMS: Fibrin glue is a therapeutic for fistulas that activates thrombin to form a fibrin clot, which mechanically seals the fistula tract. We assessed the efficacy and safety of a heterologous fibrin glue that was injected into the fistula tracts of patients with Crohn's disease (ClinicalTrials.gov No. NCT00723047).

METHODS

This multicenter, open-label, randomized controlled trial included patients with a Crohn's disease activity index < or =250 and fistulas between the anus (or low rectum) and perineum, vulva, or vagina, that drained for more than 2 months. Magnetic resonance imaging or endosonography was performed to assess fistula tracts and the absence of abscesses. Patients were stratified into groups with simple or complex fistulas and randomly assigned to receive fibrin glue injections (n = 36) or only observation (n = 41) after removal of setons. The primary end point was clinical remission at week 8, defined as the absence of draining, perianal pain, or abscesses. At week 8, a fibrin glue injection was offered to patients who were not in remission.

RESULTS

Clinical remission was observed in 13 of the 34 patients (38%) of the fibrin glue group compared with 6 of the 37 (16%) in the observation group; these findings demonstrate the benefit of fibrin glue (odds ratio, 3.2; 95% confidence interval: 1.1-9.8; P = .04). The benefit seemed to be greater in patients with simple fistulas. Four patients in the fibrin glue group and 6 in the observation group had adverse events.

CONCLUSIONS

Fibrin glue injection is a simple, effective, and well-tolerated therapeutic option for patients with Crohn's disease and perianal fistula tracts.

摘要

背景与目的

纤维蛋白胶是一种治疗瘘管的药物,它能激活凝血酶形成纤维蛋白凝块,从而机械性地封闭瘘管通道。我们评估了一种异体纤维蛋白胶在克罗恩病患者瘘管内注射的疗效和安全性(ClinicalTrials.gov 注册号:NCT00723047)。

方法

这项多中心、开放性、随机对照试验纳入了克罗恩病活动指数(CDAI)<或=250 分且存在肛门(或低位直肠)与肛周、外阴、阴道之间瘘管,且已排脓>2 个月的患者。磁共振成像或内镜超声检查用于评估瘘管和脓肿的缺失情况。患者根据瘘管单纯或复杂情况分层,在经皮窦道引流管移除后,随机分配接受纤维蛋白胶注射(n=36)或仅观察(n=41)。主要终点是第 8 周的临床缓解,定义为无排脓、肛周疼痛或脓肿。第 8 周时,对未缓解的患者给予纤维蛋白胶注射。

结果

在纤维蛋白胶组的 34 例患者中,有 13 例(38%)达到临床缓解,而在观察组的 37 例患者中,有 6 例(16%)达到缓解;这些发现表明纤维蛋白胶有效(比值比,3.2;95%置信区间:1.1-9.8;P=0.04)。单纯性瘘管患者的获益似乎更大。纤维蛋白胶组有 4 例患者和观察组有 6 例患者出现不良事件。

结论

纤维蛋白胶注射是克罗恩病伴肛周瘘管患者的一种简单、有效、耐受良好的治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验